Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus ≥10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial

[1] Groopman JE(1999)Chemotherapy-induced anemia in adults: incidence and treatment J Natl Cancer Inst 91 1616-1634

[2] Itri LM(2003)Control of cancer-related anemia with erythropoietic agents: a review of evidence for improved quality of life and clinical outcomes Ann Oncol 14 511-519

[3] Cella D(2004)The rationale for pathogen-inactivation treatment of blood components Int J Hematol 80 311-316

[4] Dobrez D(2004)Transfusion-related acute lung injury: a review Chest 126 249-258

[5] Glaspy J(2008)Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer Arch Intern Med 168 2377-2381

[6] Barbara JA(2006)Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients J Natl Cancer Inst 98 708-714

[7] Looney MR(2001)Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing J Clin Oncol 19 2875-2882

[8] Gropper MA(2003)Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study Br J Haematol 122 394-403

[9] Matthay MA(2001)Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial J Clin Oncol 19 2865-2874

[10] Khorana AA(2002)Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy J Natl Cancer Inst 94 1211-1220

[1] Groopman JE(1999)Chemotherapy-induced anemia in adults: incidence and treatment J Natl Cancer Inst 91 1616-1634

[2] Itri LM(2003)Control of cancer-related anemia with erythropoietic agents: a review of evidence for improved quality of life and clinical outcomes Ann Oncol 14 511-519

[3] Cella D(2004)The rationale for pathogen-inactivation treatment of blood components Int J Hematol 80 311-316

[4] Dobrez D(2004)Transfusion-related acute lung injury: a review Chest 126 249-258

[5] Glaspy J(2008)Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer Arch Intern Med 168 2377-2381

[6] Barbara JA(2006)Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients J Natl Cancer Inst 98 708-714

[7] Looney MR(2001)Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing J Clin Oncol 19 2875-2882

[8] Gropper MA(2003)Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study Br J Haematol 122 394-403

[9] Matthay MA(2001)Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial J Clin Oncol 19 2865-2874

[10] Khorana AA(2002)Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy J Natl Cancer Inst 94 1211-1220